[{"entities": {"persons": [{"sentiment": "none", "name": "epi procolon"}, {"sentiment": "none", "name": "epigenomics"}], "organizations": [{"sentiment": "none", "name": "edison investment research"}, {"sentiment": "none", "name": "epigenomics quickview | pharmaceutical & healthcare"}, {"sentiment": "none", "name": "fda"}, {"sentiment": "none", "name": "epigenomics"}, {"sentiment": "none", "name": "epigenomics review"}, {"sentiment": "none", "name": "crc"}, {"sentiment": "none", "name": "pma"}, {"sentiment": "none", "name": "adcom"}, {"sentiment": "none", "name": "epigenomics quickview"}, {"sentiment": "none", "name": "epi"}], "locations": [{"sentiment": "none", "name": "polymedco"}, {"sentiment": "none", "name": "us"}]}, "text": "Update | Pharmaceutical & healthcare | 13/04/2017 \nEdison Investment Research is terminating coverage on Epigenomics (ECX). Please note you should no longer rely on any previous research or estimates f... Epigenomics QuickView | Pharmaceutical & healthcare | 11/11/2016 \nEpigenomics continues to execute on the commercial front. The US is now the main market for Epi proColon, the only FDA-approved, blood-based colorecta... Epigenomics QuickView | Pharmaceutical & healthcare | 09/11/2016 \nEpigenomics has announced H116 results, which highlight the launch of Epi proColon in the US jointly with Polymedco, the largest distributor of colore... Epigenomics QuickView | Pharmaceutical & healthcare | 11/08/2016 \nEpigenomics has announced H116 results, which highlight the launch of Epi proColon in the US jointly with Polymedco, the largest distributor of colore... Epigenomics QuickView | Pharmaceutical & healthcare | 15/04/2016 \nEpigenomics has announced that the US FDA has approved Epi proColon, the company\u2019s blood-based colorectal cancer (CRC) test. The product, which ... Epigenomics QuickView | Pharmaceutical & healthcare | 13/01/2016 \nIn a surprise move, the FDA has reversed its request for a new behavioural study of Epigenomics \u2019 blood-based colorectal cancer (CRC) diagnostic ... Epigenomics QuickView | Pharmaceutical & healthcare | 10/11/2015 \nEpigenomics announced another delay to the US launch of its blood-based CRC diagnostic test Epi proColon and a moderate downgrade to its FY15 guidance... Epigenomics QuickView | Pharmaceutical & healthcare | 09/11/2015 \nThe conclusion of the behavioural study (ADMIT) may pave the way for US regulatory approval and launch of Epigenomics \u2019 novel Epi proColon bloodb... Epigenomics QuickView | Pharmaceutical & healthcare | 18/05/2015 \nEpigenomics reported 99.5% compliance of its Epi proColon CRC test in the ADMIT study. Epigenomics believes these data support its FDA application and... Epigenomics QuickView | Pharmaceutical & healthcare | 27/03/2015 \nEpigenomics is soon to conclude a behavioural study that may pave the way for US regulatory approval and launch of its novel Epi proColon blood-based ... Epigenomics QuickView | Pharmaceutical & healthcare | 08/10/2014 \nEpigenomics will shortly initiate a behavioural study that may pave the way for US regulatory approval and launch of its novel Epi proColon blood-base... Epigenomics QuickView | Pharmaceutical & healthcare | 10/07/2014 \nIn a recent meeting with the FDA, Epigenomics obtained clarity on how to design patient compliance trials, which should enable a launch of Epi proColo... Epigenomics QuickView | Pharmaceutical & healthcare | 06/05/2014 \nEpigenomics ' partner BioChain reported positive results from a Chinese clinical study of its blood-based colorectal cancer test Epi proColon, indicati... Epigenomics QuickView | Pharmaceutical & healthcare | 04/04/2014 \nEpigenomics received a marginally positive AdCom opinion in favour of Epi proColon, the only blood-based colorectal cancer CRC test. At the outset thi... Epigenomics Update | Pharmaceutical & healthcare | 14/06/2013 \nAcceptance of its PMA application and notification of priority review status puts Epigenomics \u2019 bood-based Epi proColon on track for approval in ... Epigenomics Update | Pharmaceutical & healthcare | 02/01/2013 \nEpigenomics expects to complete its PMA submission for Epi proColon, following the completion of its head-to-head study with faecal immunochemical tes... Exact Sciences QuickView | Pharmaceutical & healthcare | 27/11/2012 \nExact Sciences is on track to file a US PMA submission for its Cologuard stool-based CRC screening product in Q213, on the back of results from the &#... Epigenomics Review | Pharmaceutical & healthcare | 06/08/2012 \nEpigenomics \u2019 investment case hinges on the outcome of a non-inferiority, head-to-head study comparing Epi proColon, a blood-based colorectal can... Epigenomics Update | Pharmaceutical & healthcare | 04/04/2012 \nThe final module of a US filing for Epigenomics \u2019 blood-based colorectal cancer diagnostic, Epi proColon, hinges on the outcome of a head-to-head... Epigenomics Update | Pharmaceutical & healthcare | 19/12/2011 \nThe US FDA\u2019s confirmation that pivotal data from a 7,940-patient study of Epigenomics \u2019 blood-based colorectal cancer diagnostic, Epi proCo... Epigenomics Update | Pharmaceutical & healthcare | 24/11/2011 \nThe results of an 8,000-patient trial of Epigenomics \u2019 blood-based colorectal cancer diagnostic, Epi proColon, should be reported shortly. If pos... Epigenomics Update | Pharmaceutical & healthcare | 11/08/2011 \nEpigenomics \u2019 plans to restructure its business to focus on US sales of the Epi proColon cancer diagnostic should cut underlying administrative s... Epigenomics Outlook | Pharmaceutical & healthcare | 30/06/2011 \nEpi proColon, Epigenomics \u2019 colorectal cancer test, offers patients a simple and convenient alternative to current screening methods, and its app... Epigenomics QuickView | Pharmaceutical & healthcare | 10/03/2010 \nPRESEPT study issues have been resolved by sample retesting. The reasons for the outlier results have not been disclosed. The academic steering group ... Epigenomics QuickView | Pharmaceutical & healthcare | 08/02/2010 \nA possible cause for the variable PRESEPT laboratory data was identified as too much background fluorescence in a PCR system. Reanalysis of samples sh... Epigenomics QuickView | Pharmaceutical & healthcare | 20/01/2010 \nInitial data from the PRESEPT study on the bowel cancer test, Sept9, were released on 15 January. One laboratory had a lower detection rate than the o... About Us", "ord_in_thread": 0, "language": "english", "external_links": [], "uuid": "3cca871db84289c20d9a3816e1d661c357d13c36", "rating": null, "highlightTitle": "", "title": "Epigenomics (ECX) - Termination of coverage", "thread": {"country": "GB", "site": "edisoninvestmentresearch.com", "replies_count": 0, "title_full": "Epigenomics (ECX) - Termination of coverage", "site_categories": [], "performance_score": 0, "section_title": "Edison Investment Research - recent research", "domain_rank": null, "uuid": "3cca871db84289c20d9a3816e1d661c357d13c36", "main_image": "", "site_type": "blogs", "title": "Epigenomics (ECX) - Termination of coverage", "spam_score": 0.0, "site_section": "http://feeds.feedburner.com/EdisonInvestmentResearch", "url": "http://omgili.com/ri/jHIAmI4hxg9CUfX7sgPQ2FnXSsCJUcXw7o.qEYwULyRqA7AFBfXRxU7kgjCKXmMC8WGVvxZkw8j81QtI5.I0TQ--", "participants_count": 0, "site_full": "www.edisoninvestmentresearch.com", "social": {"linkedin": {"shares": 0}, "vk": {"shares": 0}, "facebook": {"likes": 0, "comments": 0, "shares": 0}, "gplus": {"shares": 0}, "stumbledupon": {"shares": 0}, "pinterest": {"shares": 0}}, "published": "2017-04-13T16:55:00.000+03:00"}, "crawled": "2017-04-18T11:26:47.000+03:00", "url": "http://omgili.com/ri/jHIAmI4hxg9CUfX7sgPQ2FnXSsCJUcXw7o.qEYwULyRqA7AFBfXRxU7kgjCKXmMC8WGVvxZkw8j81QtI5.I0TQ--", "highlightText": "", "published": "2017-04-13T16:55:00.000+03:00", "author": ""}]